Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Central and Eastern Europe Fund Inc
T.CEE
Primary Symbol:
CEE
The Central and Eastern Europe Fund, Inc. (the fund) is a non-diversified, closed-end management investment company. The Fund seeks long-term capital appreciation through investment in equity or equity-linked securities of issuers domiciled in Central and Eastern Europe. Under normal circumstances, the Fund invests at least 80% of its net assets (plus borrowings used for investment purposes) in securities of issuers domiciled in Central and Eastern Europe. The Fund invests in a range of sectors, such as banks; diversified telecommunication services; electric utilities; food and staples retailing; metals and mining; oil, gas, and consumable fuels; wireless telecommunication services; insurance; media; airlines, chemicals, and pharmaceuticals; entertainment; interactive media and services, information technology (IT) services; insurance, and textiles, apparel, beverages, and luxury goods. DWS International GmbH is the investment advisor of the Fund.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
NYSE:CEE - Post by User
Central and Eastern Europe Fund Inc
Bullboard Posts
(7)
•••
moneydigger
X
View Profile
View Bullboard History
Comment by
moneydigger
on Dec 07, 2009 12:51pm
346 Views
Post# 16561084
RE: Watch what happens...
RE: Watch what happens...
"Be patient...& you will be rewarded!"
I agree, nothing goes up in a straight line, add on the dips, Gold is acting very well and this drop was expected. Nothing to worry about!
Comment on this Post
Bullboard Posts
Canada Nickel unveils second of seven resources planned by mid-2025
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide
NervGen Pharma: Proof that NVG-291 works?
3 Mid-Sized Stocks to Consider This Season
Quantum eMotion leaps by 20 per cent after Becton Dickinson deal
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.